Objective
Although considerable progress has been made in treating cancer over the past decade, there are still over 8 million deaths annually from cancer worldwide. Despite considerable advances in drug discovery, resistance to chemotherapy confounds the effective treatment of cancer patients. Cancer cells can become resistant to a single drug or they may acquire broad cross-resistance to mechanistically and structurally unrelated drugs (multidrug resistance (MDR)). ATP-Binding Cassette (ABC) proteins comprise the largest protein family, many members of which are of immediate medical importance and relevant to human health. In particular, ABCB1 (MDR1-Pgp) actively extrudes many types of drugs from cancer cells, thereby conferring resistance to those agents. Thus, innate or acquired expression of P-gp is a major problem in cancer chemotherapy. The major challenge of the postgenomic era is to analyze vast amounts of data. In this context, the application of pharmacogenetics has the potential to improve the management of patients, particularly by providing the molecular basis for choosing among the increasing number of chemotherapeutic agents available for the treatment.
The basic hypothesis of this proposal is that a pharmacogenomic approach can be exploited to discover MDR1-inverse compounds that selectively kill multidrug resistant cancer cells. The proposed research utilizes a complex array of methodological tools that involves diverse state of the art techniques, such as chemoinformatic algorithms, a custom-made microarray, and biochemical assays for measuring and characterizing transport. Accomplishing the outlined aims will provide the foundation for the detailed and comprehensive framework to verify the viability of the presented hypothesis. Together, the aims help in determining the mechanism of action of MDR1-inverse compounds, setting the stage for a fresh therapeutic approach that may eventually translate into improved patient care.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance multidrug resistance
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-MOBILITY-12
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
IRG - Marie Curie actions-International re-integration grants
Coordinator
BUDAPEST
Hungary
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.